OncoMatch/Clinical Trials/NCT06941857
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Is NCT06941857 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for pancreatic cancer.
Treatment: Oxaliplatin · Irinotecan · Folinic Acid · 5-Fluorouracil (5-FU) · NC410 · Nivolumab · Ipilimumab — The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Have had prior chemotherapy for pancreatic cancer or prior chemotherapy within 5 years of enrollment for other cancer diagnoses.
Cannot have received: radiation therapy
Has received radiotherapy for pancreatic cancer.
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, or anti-Lag-3 antibodies.
Cannot have received: investigational agent
Are receiving or have received any investigational agent or used an investigational device within 28 days prior to Day 1 of treatment in this study.
Lab requirements
Blood counts
adequate organ and marrow function defined by study-specified laboratory tests and procedures
Kidney function
adequate organ and marrow function defined by study-specified laboratory tests and procedures
Liver function
adequate organ and marrow function defined by study-specified laboratory tests and procedures
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sidney Kimmel Comprehensive Cancer Center · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06941857 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages